Compare AFLAC Incorporated (AFL) vs DexCom, Inc. (DXCM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AFLAC Incorporated vs DexCom, Inc. — how do they compare? AFLAC Incorporated trades at $121.41 (market cap $61.84B), while DexCom, Inc. trades at $74.21 (market cap $28.39B). The key difference: AFLAC Incorporated is far larger — about 2.2× DexCom, Inc.'s market cap, and AFLAC Incorporated pays a 2.01% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| AFL | DXCM | |
|---|---|---|
Market Cap | $61.84B | $28.39B |
Sector | Financials | Health |
52-Week High | $121.49 | $89.53 |
52-Week Low | $98.09 | $54.84 |
Enterprise Value | $70.50B | $27.36B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aflac (AFL) trades at $121.49, up 0.5% with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a 25.32% net income margin and 16.47% ROE, though recent Q1 2026 earnings missed expectations. Analyst consensus is mixed with 28% buy ratings and a $113.57 price target below current levels. Recent developments include strong dividend performance and upcoming Q2 2026 results announcement on August 6, 2026.
The outlook remains cautiously optimistic with solid profitability and dividend stability, but faces headwinds from recent earnings misses and premium valuation pressure. Key opportunities include continued growth in Japan and U.S. markets, while risks involve medical cost inflation and uneven revenue trends. The stock's current premium to analyst targets suggests limited near-term upside potential.
DXCM trades at $73.57, up 3.26% with a bullish technical outlook and strong fundamental performance. Recent earnings beats and FDA clearances for pediatric use of Stelo CGM support growth. Revenue reached $4.66B in 2025 with net income of $836.30M, reflecting a 19.31% margin. Analyst consensus is strongly bullish with an $83.78 price target.
The outlook remains positive driven by CGM market expansion and international growth, though risks include GLP-1 drug competition and execution in non-insulin markets. Valuation at 31.06 P/E is reasonable for its growth profile, with institutional sentiment favoring further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
